コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 inant-negative mechanism to cause this fatal mitochondrial disorder.
2 he mtDNA of a young woman with a multisystem mitochondrial disorder.
3 ted in a previously unresolved multisystemic mitochondrial disorder.
4 cy, a clinically heterogeneous multisystemic mitochondrial disorder.
5 T-tubule disorder was associated with mitochondrial disorder.
6 I trial of virus-based gene transfer in this mitochondrial disorder.
7 y optic neuropathy (LHON) is the most common mitochondrial disorder.
8 is and severe encephalopathy suggestive of a mitochondrial disorder.
9 e is consistent with clinical criteria for a mitochondrial disorder.
10 o effective treatment for these or any other mitochondrial disorder.
11 ct, common findings in neurodegenerative and mitochondrial disorders.
12 Currently, there is no cure for mitochondrial disorders.
13 tools for genetic therapy of a sub-group of mitochondrial disorders.
14 ategy can be extended to correction of other mitochondrial disorders.
15 issues in a subset of patients with sporadic mitochondrial disorders.
16 actors which modulate clinical phenotypes in mitochondrial disorders.
17 in identifying pathogenic mutations causing mitochondrial disorders.
18 ' CSF align this leukodystrophy with primary mitochondrial disorders.
19 n mitochondrial translation in patients with mitochondrial disorders.
20 ormations) syndrome, Alzheimer's disease and mitochondrial disorders.
21 inking PH with hyperglycinemic syndromes and mitochondrial disorders.
22 individuals of three pedigrees that suffered mitochondrial disorders.
23 e) show promise as therapeutic compounds for mitochondrial disorders.
24 ings suggest a potential strategy to prevent mitochondrial disorders.
25 thology in Leigh Syndrome and possibly other mitochondrial disorders.
26 sia, ischemia-reperfusion injury, aging, and mitochondrial disorders.
27 n of multiple deletions as observed in other mitochondrial disorders.
28 ions leading to drastic activity changes and mitochondrial disorders.
29 brain tissues of pediatric individuals with mitochondrial disorders.
30 function, which is associated with bona fide mitochondrial disorders.
31 (CIV) assembly are a frequent cause of human mitochondrial disorders.
32 pands the clinical and molecular spectrum of mitochondrial disorders.
33 elevant for deletions observed in many human mitochondrial disorders.
34 mtDNA) deletions are associated with various mitochondrial disorders.
35 derangement and symptoms in mouse models of mitochondrial disorders.
36 t has dramatically improved the diagnosis of mitochondrial disorders.
37 tion and the tissue specificity seen in many mitochondrial disorders.
38 gnosis for four patients with three distinct mitochondrial disorders.
39 gest a provocative strategy to treat primary mitochondrial disorders.
40 he diverse clinical spectrum of POLG-related mitochondrial disorders.
41 ers, including nuclear genes associated with mitochondrial disorders.
42 , which are features often observed in human mitochondrial disorders.
43 d neurologic manifestations typifying severe mitochondrial disorders.
44 novel approach for treating SLC25A46-related mitochondrial disorders.
45 model for understanding the pathogenesis of mitochondrial disorders.
46 G) have been shown to be a frequent cause of mitochondrial disorders.
47 n COX10 have been previously associated with mitochondrial disorders.
48 ons for the study and potential treatment of mitochondrial disorders.
49 d, providing new candidate disease genes for mitochondrial disorders.
50 genetic approach to treat a number of human mitochondrial disorders.
51 mpact in the phenotype of many patients with mitochondrial disorders.
52 opathies, inherited metabolic disorders, and mitochondrial disorders (48%, 47%, and 57%, respectively
55 otor and sensory neuropathy (40/100,000) and mitochondrial disorders (9.2/100,000), the combined prev
56 he SSBP1 gene have been linked to a range of mitochondrial disorders affecting nearly all organs and
59 that are efficacious toward a wide array of mitochondrial disorders and are believed to target mitoc
62 DNA (mtDNA) deletions are a common cause of mitochondrial disorders and have been found to accumulat
64 region has been identified in patients with mitochondrial disorders and in a specific Caucasian hapl
65 o Cys mutation is encountered in humans with mitochondrial disorders and in Plasmodium species that a
67 external ophthalmoplegia (CPEO) is common in mitochondrial disorders and is frequently associated wit
68 appears to be a relatively common finding in mitochondrial disorders and is likely to benefit from ex
69 on is perturbed by mutations linked to human mitochondrial disorders and is suggested to also undergo
70 seful biomarker to detect redox imbalance in mitochondrial disorders and organic acidemias, thus prov
71 gnize the clinical syndromes suggestive of a mitochondrial disorder, and to understand the unique fea
72 n's disease, and a number of ion channel and mitochondrial disorders, and a significant start has bee
74 because potential etiologic factors include mitochondrial disorders, and genetic studies if indicate
75 DNA) mutations are a common cause of primary mitochondrial disorders, and have also been implicated i
76 taric aciduria type I, urea cycle disorders, mitochondrial disorders, and lysosomal storage disorders
81 ommon neuro-ophthalmic abnormalities seen in mitochondrial disorders are bilateral optic neuropathy,
93 ied a previously unreported genetic cause of mitochondrial disorder arising from the incompatibility
94 C1QBP deficiency represents an important mitochondrial disorder associated with a clinical spectr
95 e therapeutic potential for the treatment of mitochondrial disorders associated with heteroplasmic mt
96 COX18 is a new candidate when screening for mitochondrial disorders associated with isolated CIV def
97 n attractive system for genetic treatment of mitochondrial disorders associated with mitochondrial DN
98 r, and exercise might be beneficial for some mitochondrial disorders but contraindicated in others.
99 ncy is a frequent biochemical abnormality in mitochondrial disorders, but a large fraction of cases r
100 s have been made in determining the cause of mitochondrial disorders, but the clinical ability to dia
101 etiology of many diseases, including primary mitochondrial disorders, cancer, neurodegeneration and a
102 cephalopathy is a fatal, rapidly progressive mitochondrial disorder caused by ETHE1 mutations, whose
103 e cardiomyopathy of Barth syndrome (BTHS), a mitochondrial disorder caused by mutation of the gene en
104 ally and etiologically heterogenous group of mitochondrial disorders caused by impaired mtDNA mainten
105 hyperacetylation may be a common feature of mitochondrial disorders caused by respiratory chain defe
107 xternal ophthalmoplegia (PEO) is a heritable mitochondrial disorder characterized by the accumulation
108 inherited diabetes and deafness (MIDD) is a mitochondrial disorder characterized primarily by hearin
109 Leigh syndrome spectrum (LSS) is a primary mitochondrial disorder defined neuropathologically by a
110 heterogeneity of phenotypes in patients with mitochondrial disorders demonstrates the ongoing challen
111 ked to 3-methylglutaconic aciduria, a severe mitochondrial disorder, display diminished disaggregase
112 leukoencephalopathy is a complex II-related mitochondrial disorder for which the clinical phenotype,
113 ial DNA (mtDNA) mutations cause a variety of mitochondrial disorders for which effective treatments a
114 r syndromes, the relatively unknown field of mitochondrial disorders has become a major topic not onl
117 factor (AIF) have a strong association with mitochondrial disorders; however, little is known about
120 gamma) have been discovered in patients with mitochondrial disorders including Alpers, progressive ex
121 mutation is associated with a wide range of mitochondrial disorders, including Alpers syndrome, juve
122 ve diseases comes from similarities to known mitochondrial disorders, including delayed and variable
123 mma (Pol-gamma)) are associated with various mitochondrial disorders, including mitochondrial DNA (mt
126 we have identified candidate genes for eight mitochondrial disorders, leading to the discovery of mut
127 his first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropa
129 a mechanism by which patients suffering from mitochondrial disorders may be more susceptible to renal
130 ed oxidative phosphorylation (OXPHOS) in two mitochondrial disorders, NARP (neuropathy, ataxia and re
131 ATP6 gene are known to cause several related mitochondrial disorders: NARP (neuropathy, ataxia, and r
132 is implicated in various diseases, including mitochondrial disorders, neurodegeneration, and diabetes
133 e range of human diseases, including primary mitochondrial disorders, neurodegeneration, cancer, and
134 d mitochondrial ATP synthesis in two related mitochondrial disorders: neuropathy, ataxia and retiniti
135 tions in SCO1 and SCO2 associated with fatal mitochondrial disorders, one lies in a highly conserved
137 errors of OXPHOS function are termed primary mitochondrial disorders (PMDs), and the use of nutrition
138 drial biology and disease, and as a model of mitochondrial disorders potentially amenable to the deve
139 x I deficiency is the most commonly reported mitochondrial disorder presenting in childhood, but the
146 es (MDDS) are rare, clinically heterogeneous mitochondrial disorders resulting from nuclear variants
147 linked to multiple human diseases, including mitochondrial disorders, susceptibility to viral infecti
148 eigh Syndrome French Canadian Type (LSFC), a mitochondrial disorder that includes diagnostic liver dy
149 und in a group of 10 patients with a primary mitochondrial disorder that showed a normal proton efflu
150 therapeutic targets for two human hereditary mitochondrial disorders that reflect the ongoing effect
151 h DdCBE is a promising gene therapy tool for mitochondrial disorders, the doses of the therapeutic co
152 d disease progression are common features of mitochondrial disorders they carry substantial morbidity
154 causes Leigh syndrome (LS, OMIM # 256000), a mitochondrial disorder typified by stress-induced metabo
155 opathies, inherited metabolic disorders, and mitochondrial disorders were diagnosed in neonatal/early
156 lar, metabolic, inflammatory, dysimmune, and mitochondrial disorders were excluded and none had sever
158 tions are the most common cause of inherited mitochondrial disorders, with as many as 2% of the popul
159 l diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a furth